On April 3, 2026, Denali Therapeutics Inc. (Nasdaq: DNLI) announced the termination of its collaboration agreement with Takeda regarding the co-development and co-commercialization of DNL593 (PTV:PGRN). The decision to terminate the agreement was made by Takeda for strategic reasons and was not influenced by the efficacy or safety data of the drug. DNL593 is an experimental progranulin replacement therapy that utilizes Denali’s Protein Transport Vehicle™ (PTV) to transport progranulin across the blood-brain barrier for the treatment of frontotemporal dementia-granulin (FTD-GRN). Denali will now resume full control of DNL593 and its associated intellectual property portfolio.